You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers are wondering how the COVID-19 pandemic may affect results from clinical trials that continued and how to account for that influence, ScienceInsider reports.
The Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll patients into the PREDICT trial.
The New York Times reports Pfizer and BioNTech have also started a trial of their mRNA-based vaccine for SARS-CoV-2 in the US.
Early trials give conflicting results on remdesivir to treat COVID-19, though a large trial suggests it shortens disease length, Nature News reports.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Two experimental drugs were unable to slow or prevent Alzheimer's disease among people at high genetic risk, the Associated Press reports.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
New Scientist reports that cancer patients treated with immune cells that underwent CRISPR-based gene editing exhibited no serious side effects.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.